PMID- 9264349
OWN - NLM
STAT- MEDLINE
DCOM- 19970903
LR  - 20181130
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 80
IP  - 4
DP  - 1997 Aug 15
TI  - Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications 
      for pathogenesis.
PG  - 668-75
AB  - BACKGROUND: Neuroendocrine tumors of the gastroenteropancreatic system include 
      pancreatic islet cell and carcinoid tumors. These tumors comprise a functionally 
      and biologically heterogeneous group of neoplasms that rarely show reliable 
      histopathologic signs of malignancy. No etiologic factors are proven to be 
      associated with them, and their exact ontogeny and carcinogenesis remain unknown. 
      METHODS: Monoclonal antibodies were employed, along with microwave antigen 
      retrieval and the avidin-biotin immunohistochemical method, to investigate the 
      expression of c-myc, bcl-2, c-erb B-2, c-erb B-3, c-jun, and proliferating cell 
      nuclear antigen (PCNA) in a retrospective series of 116 primary 
      gastroenteropancreatic neuroendocrine tumors (GPNTs). The authors attempted to 
      correlate this expression with the clinicopathologic outcome of the disease. 
      RESULTS: Immunoreactivities for c-myc, bcl-2, c-erb B-2, c-erb B-3, and c-jun 
      were detected in 100%, 45%, 24%, 7%, and 24% of pancreatic neuroendocrine tumors 
      (PNTs), respectively. In carcinoid tumors, immunoreactivities were detected for 
      c-myc (63%), bcl-2 (28%), c-erb B-2 (31%), c-erb B-3 (6%), and c-jun (23%). There 
      were significantly higher incidences of c-myc, bcl-2, and c-erb B-2 
      immunoreactivities in carcinoid tumors of the rectum than in those of the 
      appendix, and significantly higher incidences of bcl-2 and c-jun 
      immunoreactivities in carcinoid tumors of the bronchus than in those of the 
      appendix. Incidence of PCNA immunoreactivity was significantly higher in 
      malignant than in benign PNTs and also significantly higher in carcinoid tumors 
      of the jejunum and ileum than in those of the appendix. CONCLUSIONS: The 
      oncogenes c-myc, bcl-2, c-erb B-2, and c-jun are frequently expressed in human 
      GPNTs. The expression of these oncogenes may represent pathogenic events in the 
      generation, malignant transformation, and progression of GPNTs. The 
      immunohistochemical evaluation of cell kinetics in GPNTs by PCNA might be a 
      useful adjunct to conventional diagnostic procedures.
FAU - Wang, D G
AU  - Wang DG
AD  - Division of Metabolism and Endocrinology, School of Clinical Medicine, The 
      Queen's University of Belfast, United Kingdom.
FAU - Johnston, C F
AU  - Johnston CF
FAU - Buchanan, K D
AU  - Buchanan KD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-jun)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (Receptor, ErbB-3)
SB  - IM
MH  - ErbB Receptors/analysis
MH  - Gastrointestinal Neoplasms/*genetics/metabolism/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Neuroendocrine Tumors/*genetics/metabolism/pathology
MH  - Pancreatic Neoplasms/*genetics
MH  - Proliferating Cell Nuclear Antigen/analysis
MH  - Proto-Oncogene Proteins/*analysis
MH  - Proto-Oncogene Proteins c-bcl-2/analysis
MH  - Proto-Oncogene Proteins c-jun/analysis
MH  - Proto-Oncogene Proteins c-myc/analysis
MH  - Receptor, ErbB-2/analysis
MH  - Receptor, ErbB-3
MH  - Retrospective Studies
EDAT- 1997/08/15 00:00
MHDA- 2000/06/20 09:00
CRDT- 1997/08/15 00:00
PHST- 1997/08/15 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1997/08/15 00:00 [entrez]
AID - 10.1002/(SICI)1097-0142(19970815)80:4<668::AID-CNCR4>3.0.CO;2-J [pii]
PST - ppublish
SO  - Cancer. 1997 Aug 15;80(4):668-75.